Stockscreener 앱 받기
1.01
0.00%
0.00
시간 외 거래:
1.01
Revelation Biosciences Inc 주식(REVB)의 최신 뉴스
Revelation Biosciences Inc. Warrant (REVBW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Stock News, REVB Share Price & Updates - Kalkine
Revelation Biosciences Inc. Warrant (REVBW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Revelation Biosciences (REVB) Climbs 3.13% to $1.02 as Micro-Cap Biotech Tests RangeSymmetrical Triangle - vinanet.vn
Revelation Biosciences Inc (REVBU) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Revelation (REVB) Technicals: Ends Higher by 0.92% at $1.10 at the Close; Technical View: Traders Can Monitor the $1.04-$1.16 Range in the Current UpdateVanna Flow - vinanet.vn
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Enterprise value to EBIT forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Enterprise value to revenue forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Revelation Biosciences Grants Performance-Based Restricted Stock to CEO and CFO - Minichart
Form 8K Revelation Biosciences Inc For: 19 August By Investing.com - Investing.com Nigeria
Revelation Biosciences grants restricted stock awards to CEO and CFO - Investing.com
Revelation Biosciences Grants Performance-Based Executive Stock Awards - TipRanks
Revelation Biosciences grants restricted shares to James Rolke and Chester S. Zygmont III - TradingView
Revelation Biosciences (REVB) ties CEO, CFO pay to $30–120M cap tests - Stock Titan
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - biospace.com
Revelation Biosciences selects CRO for phase 2/3 AKI study By Investing.com - Investing.com Canada
Revelation Biosciences selects CRO for phase 2/3 AKI study - Investing.com
Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study - TradingView
Revelation Biosciences (REVB) CFO gifts 416K shares - Stock Titan
Revelation Biosciences (NASDAQ: REVB) grants director 32K restricted shares - Stock Titan
Revelation Biosciences (NASDAQ: REVB) details insider trade - Stock Titan
Revelation Biosciences (REVB) insider logs stock trade in company shares - Stock Titan
Armistice Capital (REVB) discloses 4.99% Revelation Biosciences stake via Master Fund - Stock Titan
REVB Q2 2026 Earnings: Loss per Share Misses Consensus as Pre-Revenue Pipeline AdvancesCFO Commentary Report - Vinanet
Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences, Inc. (REVBW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revelation Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Revelation Biosciences reports $3.3M net loss for Q2 2026, $11.5M cash on hand - TradingView
BRIEF-Revelation Biosciences Inc Q2 EPS USD -0.87 - TradingView
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Yahoo Finance
REVELATION BIOSCIENCES 2Q 2026: Net loss $(3.32M), EPS $(0.87) — 10-Q Summary - TradingView
Revelation Biosciences (Nasdaq: REVB) posts Q2 loss and flags cash risk - Stock Titan
REVB Q2'26 Earnings: EPS estimate is (0.83) USD - TradingView
REVB: Q2 net loss widened to $3.3M; Gemini targets a $94B market with cash runway through Q1 2027 - TradingView
Revelation Biosciences Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - New Castle News
Revelation Biosciences (NASDAQ:REVB) secures FDA agreement setting single-study path for kidney drug Gemini - Kalkine
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
REVB|Revelation Biosciences Inc|Price:1.050|Chg%:-0.010 - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey
REVB Q1 2026 Earnings: Significant EPS Miss with No Revenue ReportedOne-Time Gain Impact - vinanet.vn
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Inc. (REVB) Holds Steady at $1.15 as Consolidation ContinuesSentiment Shift - po-news-eg.net
Three New Hires Get Revelation Biosciences Stock Awards Through 2028 - Stock Titan
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Corinthian
REVB Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageFinancial Health Score - vinanet.vn
REVB Q1 2026 Earnings: Net Loss Widens on R&D Investments; Shares Edge HigherEarnings Miss Alert - vinanet.vn
Revelation Biosciences Adopts Stockholder Rights Plan to Protect Investors and Maximize Value - Minichart
Revelation Biosciences Adopts Stockholder Rights Protection Plan - TipRanks
Why Is Revelation Biosciences (NASDAQ:REVB) in Focus Today? - Kalkine Media
Revelation Biosciences Announces Adoption of Stockholder Rights Plan - ACCESS Newswire
0.86%
0.31%
자본화:
|
볼륨(24시간):